4.5 Article

Expression of candidate tumor suppressor gene ING2 is lost in non-small cell lung carcinoma

期刊

LUNG CANCER
卷 69, 期 2, 页码 180-186

出版社

ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2009.11.006

关键词

ING1; ING3; ING4; ING5

资金

  1. INCa
  2. La Fondation pour la Recherche Medicate
  3. IASLC (International Association for the Study of Lung Cancer)
  4. INSERM
  5. La Ligue Contre le Cancer
  6. PNES Poumon
  7. Marie Curie International Reintegration [MIRG-CT-2006-042148]

向作者/读者索取更多资源

ING2 is a candidate tumor suppressor gene involved in cell cycle control, apoptosis and senescence. Furthermore, we have recently shown that loss of ING2 expression is associated with increased genome instability. We investigated its status in a series of 120 non-small cell lung cancer (NSCLC) by using immunohistochemistry (IHC). The results showed that ING2 protein expression is downregulated in more than 50% of NSCLC, with a higher frequency in adenocarcinoma (ADK) as compared to squamous cell carcinoma (SCC) (68% versus 45%, P = 0.021). Loss of ING2 expression occurs in a high proportion of tumors from stage I and was not associated with patient's gender, age and 5-year survival. When investigating the possible mechanisms responsible for the decrease of ING2 expression, we did not observe any loss of heterozygosity or mutation in the ING2 gene. However, in 95% of the cases examined, we identified a silent single nucleotide polymorphism (SNP). By using quantitative RT-PCR, we found that ING2 loss of expression may be due to the decrease of its mRNA level. Analysis of CpG islands present in the promoter region of the ING2 gene did not allow for the detection of methylation. Mechanistically, although p53 can regulate ING2 transcription and ING2 enhances p53 activity, no correlation between ING2 and p53 IHC status was observed. Overall, these results indicate that loss of ING2 expression could contribute to lung tumorigenesis independently of p53. (C) 2009 Elsevier Ireland Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J. Hochmair, Mustafa Ozguroglu, Jun Ho Ji, Marina Chiara Garassino, Oleksandr Voitko, Artem Poltoratskiy, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Kazarnowicz, Gyorgy Losonczy, Nikolay V. Conev, Jon Armstrong, Natalie Byrne, Piruntha Thiyagarajah, Haiyi Jiang, Luis Paz-Ares

Summary: The study showed that first-line treatment with durvalumab plus platinum-etoposide resulted in sustained improvement in overall survival, while the addition of tremelimumab to this combination did not significantly enhance efficacy. These findings support the use of durvalumab plus platinum-etoposide as a new standard of care for extensive-stage small-cell lung cancer.

LANCET ONCOLOGY (2021)

Article Oncology

PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project

H. Blons, J-B Oudart, J-P Merlio, D. Debieuvre, F. de Fraipont, C. Audigier-Valette, F. Escande, S. Hominal, P-P Bringuier, S. Fraboulet-Moreau, L. Ouafik, D. Moro-Sibilot, A. Lemoine, A. Langlais, P. Missy, F. Morin, P-J Souquet, F. Barlesi, J. Cadranel, M. Beau-Faller

Summary: Tumor mutation screening is crucial for patients with stage IV NSCLC, and identifying co-occurring alterations, such as PTEN, ATM, IDH1, and KRAS mutations, can impact the response and prognosis to first line EGFR TKI therapy. These findings may offer new treatment options for patients with unfavorable genotypes to improve their initial treatment responses.

LUNG CANCER (2021)

Article Oncology

Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

S. Peters, J-L Pujol, U. Dafni, M. Domine, S. Popat, M. Reck, J. Andrade, A. Becker, D. Moro-Sibilot, A. Curioni-Fontecedro, O. Molinier, K. Nackaerts, A. Insa Molla, R. Gervais, G. Lopez Vivanco, J. Madelaine, J. Mazieres, M. Faehling, F. Griesinger, M. Majem, J. L. Gonzalez Larriba, M. Provencio Pulla, K. Vervita, H. Roschitzki-Voser, B. Ruepp, P. Mitchell, R. A. Stahel, C. Le Pechoux, D. De Ruysscher

Summary: The STIMULI trial did not demonstrate improvement in PFS with nivolumab-ipilimumab consolidation after chemo-radiotherapy in limited-disease small-cell lung cancer. The higher rates of grade >= 3 adverse events and treatment discontinuation in the experimental arm may have influenced the efficacy results.

ANNALS OF ONCOLOGY (2022)

Article Oncology

Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial

Julien Mazieres, Claire Lafitte, Charles Ricordel, Laurent Greillier, Elodie Negre, Gerard Zalcman, Charlotte Domblides, Jeannick Madelaine, Jaafar Bennouna, Celine Mascaux, Denis Moro-Sibilot, Francois Pinquie, Alexis B. Cortot, Josiane Otto, Jacques Cadranel, Alexandra Langlais, Franck Morin, Virginie Westeel, Benjamin Besse

Summary: This study evaluated the efficacy of a triple therapy with HER2-targeted antibodies and docetaxel in HER2-mutated NSCLC patients, demonstrating feasibility and effectiveness of this approach, highlighting the potential benefit of HER2 antibody-based strategy in this subset of patients.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Article Oncology

IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain

Naoyuki Nogami, Fabrice Barlesi, Mark A. Socinski, Martin Reck, Christian A. Thomas, Federico Cappuzzo, Tony S. K. Mok, Gene Finley, Joachim G. Aerts, Francisco Orlandi, Denis Moro-Sibilot, Robert M. Jotte, Daniil Stroyakovskiy, Liza C. Villaruz, Delvys Rodriguez-Abreu, Darren Wan-Teck Lim, David Merritt, Shelley Coleman, Anthony Lee, Geetha Shankar, Wei Yu, Ilze Bara, Makoto Nishio

Summary: This study presents the final overall survival (OS) analyses for EGFR mutations and liver or brain metastases subgroups in the IMpower150 study. The results show that ABCP has sustained OS improvements compared to BCP in sensitizing EGFR mutations and baseline liver metastases subgroups. However, ACP does not provide a survival benefit in these subgroups compared to BCP. The study also suggests further investigation into the impact of ABCP on delaying the development of new brain lesions.

JOURNAL OF THORACIC ONCOLOGY (2022)

Article Oncology

Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trial

Pierre-Jean Souquet, Clarisse Audigier-Valette, Olivier Molinier, Alexis Cortot, Jacques Margery, Lionel Moreau, Radj Gervais, Fabrice Barlesi, Eric Pichon, Gerard Zalcman, Patrick Dumont, Nicolas Girard, Michel Poudenx, Julien Mazieres, Jacques Cadranel, Didier Debieuvre, Jerome Dauba, Alexandra Langlais, Franck Morin, Denis Moro-Sibilot, Virginie Westeel, Maurice Perol

Summary: Adapting maintenance strategy according to response to induction chemotherapy does not improve patient outcome in advanced non-squamous non-small cell lung cancer.

LUNG CANCER (2022)

Article Oncology

Detection of acquired TERT amplification in addition to predisposing p53 and Rb pathways alterations in EGFR-mutant lung adenocarcinomas transformed into small-cell lung cancers

Anne Mc Leer, Matthieu Foll, Marie Brevet, Martine Antoine, Silvia Novello, Julie Mondet, Jacques Cadranel, Nicolas Girard, Matteo Giaj Levra, Pierre Demontrond, Clarisse Audigier-Valette, Eric Letouze, Sylvie Lantuejoul, Lynnette Fernandez-Cuesta, Denis Moro-Sibilot

Summary: In EGFR-LUAD patients who develop resistance to EGFR-TKIs and undergo histological transformation to SCLC, mutations in TP53 and alterations in the Rb pathway are common genetic changes predisposing to SCLC transformation. Additionally, TERT amplification has been identified as another common genetic mechanism acquired during SCLC transformation in this subset of patients.

LUNG CANCER (2022)

Article Nanoscience & Nanotechnology

Radiosensitizing Fe-Au nanocapsules (hybridosomes®) increase survival of GL261 brain tumor-bearing mice treated by radiotherapy

Clement Goubault, Ulrich Jarry, Megane Bostoen, Pierre-Antoine Eliat, Myrtil L. Kahn, Remy Pedeux, Thierry Guillaudeux, Fabienne Gauffre, Soizic Chevance

Summary: This study evaluated the potentiating effect of hollow shells made of gold and iron oxide nanoparticles on radiotherapy for glioblastoma. The results showed a significant effect of gold nanoparticles in radiotherapy, while iron oxide had no beneficial effects. The study also found that injected hybridosomes(R) remained near the brain tumor for several days in vivo. These findings provide a proof-of-concept for the effectiveness of hybridosomes(R) as tools for the development of combined therapies.

NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2022)

Article Biochemistry & Molecular Biology

Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer

Lisa Derosa, Bertrand Routy, Andrew Maltez Thomas, Valerio Iebba, Gerard Zalcman, Sylvie Friard, Julien Mazieres, Clarisse Audigier-Valette, Denis Moro-Sibilot, Francois Goldwasser, Carolina Alves Costa Silva, Safae Terrisse, Melodie Bonvalet, Arnaud Scherpereel, Herve Pegliasco, Corentin Richard, Francois Ghiringhelli, Arielle Elkrief, Antoine Desilets, Felix Blanc-Durand, Fabio Cumbo, Aitor Blanco, Romain Boidot, Sandy Chevrier, Romain Daillere, Guido Kroemer, Laurie Alla, Nicolas Pons, Emmanuelle Le Chatelier, Nathalie Galleron, Hugo Roume, Agathe Dubuisson, Nicole Bouchard, Meriem Messaoudene, Damien Drubay, Eric Deutsch, Fabrice Barlesi, David Planchard, Nicola Segata, Stephanie Martinez, Laurence Zitvogel, Jean-Charles Soria, Benjamin Besse

Summary: In addition to PD-L1 expression, biomarkers for predicting the response to immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer (NSCLC) are needed. This study found that fecal Akkermansia muciniphila (Akk) was associated with clinical benefit of ICI treatment in NSCLC patients, independent of PD-L1 expression and other factors. The relative abundance of Akk in the gut microbiome may serve as a potential biomarker for patient stratification.

NATURE MEDICINE (2022)

Article Oncology

IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer

O. Molinier, B. Besse, F. Barlesi, C. Audigier-Valette, S. Friard, I Monnet, G. Jeannin, J. Mazieres, J. Cadranel, J. Hureaux, W. Hilgers, E. Quoix, B. Coudert, D. Moro-Sibilot, E. Fauchon, V Westeel, P. Brun, A. Langlais, F. Morin, P. J. Souquet, N. Girard

Summary: This study examined the efficacy and safety of nivolumab, an immune checkpoint inhibitor, in patients with advanced refractory non-small-cell lung cancer. The results showed that nivolumab had a significant effect, and the study identified prognostic factors that influenced the patients' survival rates.

ESMO OPEN (2022)

Article Biology

Stress-induced tyrosine phosphorylation of RtcB modulates IRE1 activity and signaling outputs

Alexandra Papaioannou, Federica Centonze, Alice Metais, Marion Maurel, Luc Negroni, Matias Gonzalez-Quiroz, Sayyed Jalil Mahdizadeh, Gabriella Svensson, Ensieh Zare, Alice Blondel, Albert C. Koong, Claudio Hetz, Remy Pedeux, Michel L. Tremblay, Leif A. Eriksson, Eric Chevet

Summary: The IRE1 alpha RNase regulatory network is dynamically regulated by tyrosine kinases and phosphatases. The extent of RtcB tyrosine phosphorylation determines cell adaptive or death outputs.

LIFE SCIENCE ALLIANCE (2022)

Article Oncology

Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort

Simon Baldacci, Benjamin Besse, Virginie Avrillon, Bertrand Mennecier, Julien Mazieres, Pascale Dubray-Longeras, Alexis B. Cortot, Renaud Descourt, Helene Doubre, Xavier Quantin, Michael Duruisseaux, Isabelle Monnet, Denis Moro-Sibilot, Jacques Cadranel, Christelle Clement-Duchene, Sophie Cousin, Charles Ricordel, Patrick Merle, Josiane Otto, Sophie Schneider, Alexandra Langlais, Franck Morin, Virginie Westeel, Nicolas Girard

Summary: In this study, the researchers evaluated the treatment sequencing, efficacy, and safety of lorlatinib in patients with ALK+ NSCLC through the French Expanded Access Program. The results showed that lorlatinib provided significant clinical benefit and high intracerebral antitumor activity in heavily pretreated patients with ALK+ NSCLC.

EUROPEAN JOURNAL OF CANCER (2022)

Article Oncology

A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT-0701 MAPS phase 3 trial

Elodie Maille, Jerome Levallet, Fatemeh Dubois, Martine Antoine, Claire Danel, Christian Creveuil, Julien Mazieres, Jacques Margery, Laurent Greillier, Valerie Gounant, Denis Moro-Sibilot, Olivier Molinier, Herve Lena, Isabelle Monnet, Emmanuel Bergot, Alexandra Langlais, Franck Morin, Arnaud Sherpereel, Gerard Zalcman, Guenaelle Levallet

Summary: This study suggests that high cytosolic AREG expression is associated with better prognosis in malignant pleural mesothelioma (MPM). However, tumor cells fail to correctly process and release AREG, leading to inconsistency between its expression in plasma and tumor cells. Therefore, mesothelioma cell AREG content may serve as a prognostic marker.

INTERNATIONAL JOURNAL OF CANCER (2022)

Article Oncology

Characterization of the Peri-Membrane Fluorescence Phenomenon Allowing the Detection of Urothelial Tumor Cells in Urine

Charly Gutierrez, Xavier Pinson, Kathleen Jarnouen, Marine Charpentier, Raphael Pineau, Laetitia Lallement, Remy Pedeux

Summary: Urinary cytology is a non-invasive and easy-to-collect method for detecting bladder cancer. It is effective for high-grade bladder cancer, but less effective for low-grade cancer. Recent research has found that the fluorescent properties of urothelial tumor cells in urinary cytology, known as peri-membrane fluorescence, can improve early detection of bladder cancer.

CANCERS (2022)

Article Oncology

Lorlatinib for advanced ROS1+non-small-cell lung cancer: results of the IFCT-1803 LORLATU study

N. Girard, S. Galland-Girodet, V Avrillon, B. Besse, M. Duruisseaux, J. Cadranel, J. Otto, A. Prevost, B. Roch, J. Bennouna, K. Bouledrak, M. Coudurier, T. Egenod, R. Lamy, C. Ricordel, D. Moro-Sibilot, L. Odier, J. Tillon-Strozyk, G. Zalcman, P. Missy, V Westeel, S. Baldacci

Summary: This study investigates the efficacy and safety of lorlatinib in patients with ROS1-rearranged non-small-cell lung cancer (ROS1thorn NSCLC) treated through an expanded access program. The results suggest that lorlatinib is a major treatment option for advanced refractory ROS1thorn NSCLC in the treatment strategy.

ESMO OPEN (2022)

暂无数据